COMPUMED INC Form 8-K October 15, 2007

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2007

COMPUMED, INC.

(Exact name of registrant as specified in its charter)

DELAWARE 000-14210 95-2860434

(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

5777 West Century Blvd., Suite 1285, Los Angeles, CA 90045

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code:		(310) 258-5000
(Former nam	ne or former address, if changed since last repo	rt)
	orm 8-K filing is intended to simultaneously saprovisions (see General Instruction A.2. below	
	Rule 425 under the Securities Act (17 CFR 230	
	4a-12 under the Exchange Act (17 CFR 240.14	
[] Fre-commencement communications	pursuant to Rule 14d-2(b) under the Exchange	ACI (17 CFR 240.14d-2(0))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01

REGULATION FD DISCLOSURE.

On October 15, 2007, CompuMed, Inc. issued a press release today announcing the United States Patent and Trademark Office has issued the company a patent for an automated method and system to assess or monitor the extent or progression of joint-damaging diseases such as osteoarthritis and rheumatoid arthritis. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference."

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

EXHIBIT DESCRIPTION

NUMBER

99.1 <u>Compumed, Inc. awarded US Patent for technology to monitor joint disease.</u>

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CompuMed, Inc.

(Registrant)

Date: October 15, 2007 By: /s/ Maurizio Vecchione

Maurizio Vecchione

Interim Chief Executive Officer